Allopregnanolone Reinstates Tyrosine Hydroxylase Immunoreactive Neurons and Motor Performance in an MPTP-Lesioned Mouse Model of Parkinson's Disease

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Adeosun, Samuel O ^b   Hou, Xu ^b   Jiao, Yun ^c   Zheng, Baoying ^a   Henry, Sherry ^a   Hill, Rosanne ^a   He, Zhi ^a   Pani, Amar ^c   Kyle, Patrick ^a   Ou, Xiaoming ^a,b   Mosley, Thomas ^b   Farley, Jerry M ^a,b   Stockmeier, Craig ^a,b   Paul, Ian ^a,b   Bigler, Steven ^a   Brinton, Roberta Diaz ^d   Smeyne, Richard ^c   Wang, Jun Ming ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ALLOPREGNANOLONE ALPHA; DOPAMINE; NEUROSTEROID; NORADRENALIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY EQUILIBRIUM; CELL CYCLE S PHASE; CONTROLLED STUDY; COORDINATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE AMPLIFICATION; IMMUNOREACTIVITY; MALE; MESENCEPHALON; MOTOR PERFORMANCE; MOUSE; NERVE CELL DIFFERENTIATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; ROTAROD TEST; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MESENCEPHALON; MICE; MPTP POISONING; NEURONS; NOREPINEPHRINE; PREGNANOLONE; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84870487990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050040     Document Type: Article

References (69)

1. Lindvall O, Kokaia Z, (2010) Stem cells in human neurodegenerative disorders-time for clinical translation? J Clin Invest 120: 29-40.
2. Wang JM, Irwin RW, Liu L, Chen S, Brinton RD, (2007) Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res 4: 510-517.
3. Wang JM, Singh C, Liu L, Irwin RW, Chen S, et al. (2010) Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 107: 6498-6503.
4. Wang JM, Sun C, (2010) Calcium and neurogenesis in Alzheimer's disease. Front Neurosci 4: 194.
5. Williams CA, Lavik EB, (2009) Engineering the CNS stem cell microenvironment. Regen Med 4: 865-877.
6. Wang JM, Johnston PB, Ball BG, Brinton RD, (2005) The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25: 4706-4718.
7. Charalampopoulos I, Alexaki VI, Tsatsanis C, Minas V, Dermitzaki E, et al. (2006) Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann N Y Acad Sci 1088: 139-152.
8. Charalampopoulos I, Margioris AN, Gravanis A, (2008) Neurosteroid dehydroepiandrosterone exerts anti-apoptotic effects by membrane-mediated, integrated genomic and non-genomic pro-survival signaling pathways. J Neurochem 107: 1457-1469.
9. Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML, (2004) Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 153: 13-17.
10. Wang JM, Brinton RD, (2008) Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci 9 Suppl 2: S11.
11. Wang JM, Liu L, Irwin RW, Chen S, Brinton RD, (2008) Regenerative potential of allopregnanolone. Brain Res Rev 57: 398-409.
12. Sun C, Ou X, Farley JM, Stockmeier C, Bigler S, et al. (2012) Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of Triple Transgenic Mouse Model of Alzheimer's Disease. Curr Alzheimer Res In press.
13. Smeyne RJ, Jackson-Lewis V, (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134: 57-66.
14. Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, et al. (2007) Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175: 107-116.
15. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S, (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-269.
16. Gomez-Pinilla F, Dao L, So V, (1997) Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res 764: 1-8.
17. Nelson EL, Liang CL, Sinton CM, German DC, (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J Comp Neurol 369: 361-371.
18. Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI, (2010) Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacol Biochem Behav 95: 466-472.
19. Gorton LM, Vuckovic MG, Vertelkina N, Petzinger GM, Jakowec MW, et al. (2010) Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res 213: 253-262.
20. Mochizuki H, (2009) [Current status of gene therapy for Parkinson disease]. Brain Nerve 61: 485-493.
21. Yasuda T, Hayakawa H, Nihira T, Ren YR, Nakata Y, et al. (2011) Parkin-Mediated Protection of Dopaminergic Neurons in a Chronic MPTP-Minipump Mouse Model of Parkinson Disease. J Neuropathol Exp Neurol 70: 686-697.
22. Mochizuki H, Yasuda T, Hayakawa H, Nihira T, Ren YR, et al. (2011) Parkin-Mediated Protection of Dopaminergic Neurons in a Chronic MPTP-Minipump Mouse Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology 70: 686-697.
23. Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, et al. (2009) TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. European Journal of Pharmacology 620: 42-48.
24. Kubo S, Kamigaichi R, Ishikawa K, Yokoyama K, Ogaki K, et al. (2009) Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report. European Journal of Neurology 16: E6-E6.
25. Mochizuki H, Yasuda T, Nihira T, Ren YR, Cao XQ, et al. (2009) Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. Journal of Neurochemistry 108: 932-944.
26. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, et al. (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A 104: 13804-13809.
27. Rommelfanger KS, Weinshenker D, (2007) Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74: 177-190.
28. Zarow C, Lyness SA, Mortimer JA, Chui HC, (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341.
29. Gerecke KM, Jiao Y, Pani A, Pagala V, Smeyne RJ, (2010) Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res 1341: 72-83.
30. Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, et al. (2010) Exercise exerts neuroprotective effects on Parkinson's disease model of rats. Brain Res 1310: 200-207.
31. Daadi MM, Weiss S, (1999) Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. J Neurosci 19: 4484-4497.
32. Peng J, Andersen JK, (2011) Mutant alpha-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Aging Cell 10: 255-262.
33. Peng J, Oo ML, Andersen JK, (2010) Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 115: 1363-1373.
34. Peng J, Xie L, Jin K, Greenberg DA, Andersen JK, (2008) Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience 153: 664-670.
35. Shan X, Chi L, Bishop M, Luo C, Lien L, et al. (2006) Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 24: 1280-1287.
36. Parish CL, Beljajeva A, Arenas E, Simon A, (2007) Midbrain dopaminergic neurogenesis and behavioural recovery in a salamander lesion-induced regeneration model. Development 134: 2881-2887.
37. Berg DA, Kirkham M, Beljajeva A, Knapp D, Habermann B, et al. (2010) Efficient regeneration by activation of neurogenesis in homeostatically quiescent regions of the adult vertebrate brain. Development 137: 4127-4134.
38. Berg DA, Kirkham M, Wang H, Frisen J, Simon A, (2011) Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell 8: 426-433.
39. Lee DA, Bedont JL, Pak T, Wang H, Song J, et al. (2012) Tanycytes of the hypothalamic median eminence form a diet-responsive neurogenic niche. Nat Neurosci 15: 700-702.
40. Bonfanti L, Ponti G, (2008) Adult mammalian neurogenesis and the New Zealand white rabbit. Vet J 175: 310-331.
41. Hajihosseini MK, De Langhe S, Lana-Elola E, Morrison H, Sparshott N, et al. (2008) Localization and fate of Fgf10-expressing cells in the adult mouse brain implicate Fgf10 in control of neurogenesis. Mol Cell Neurosci 37: 857-868.
42. Ponti G, Conti L, Cataudella T, Zuccato C, Magrassi L, et al. (2005) Comparative expression profiles of ShcB and ShcC phosphotyrosine adapter molecules in the adult brain. Neuroscience 133: 105-115.
43. Ponti G, Crociara P, Armentano M, Bonfanti L, (2010) Adult neurogenesis without germinal layers: the "atypical" cerebellum of rabbits. Arch Ital Biol 148: 147-158.
44. Ponti G, Peretto P, Bonfanti L, (2006) A subpial, transitory germinal zone forms chains of neuronal precursors in the rabbit cerebellum. Dev Biol 294: 168-180.
45. Ponti G, Peretto P, Bonfanti L, (2008) Genesis of neuronal and glial progenitors in the cerebellar cortex of peripuberal and adult rabbits. PLoS One 3: e2366.
46. Arias-Carrion O, Yamada E, Freundlieb N, Djufri M, Maurer L, et al. (2009) Neurogenesis in substantia nigra of parkinsonian brains? J Neural Transm Suppl: 279-285.
47. Yoshimi K, Ren YR, Seki T, Yamada M, Ooizumi H, et al. (2005) Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 58: 31-40.
48. Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, et al. (2003) Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 100: 7925-7930.
49. Cabras S, Saba F, Reali C, Scorciapino ML, Sirigu A, et al. (2010) Antidepressant imipramine induces human astrocytes to differentiate into cells with neuronal phenotype. Int J Neuropsychopharmacol 13: 603-615.
50. Ming GL, Song H, (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70: 687-702.
51. Matsuura N, Lie DC, Hoshimaru M, Asahi M, Hojo M, et al. (2001) Sonic Hedgehog Facilitates Dopamine Differentiation in the Presence of a Mesencephalic Glial Cell Line. J Neurosci 21: 4326-4335.
52. Gago N, El-Etr M, Sananes N, Cadepond F, Samuel D, et al. (2004) 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res 78: 770-783.
53. Lauber ME, Lichtensteiger W, (1996) Ontogeny of 5 alpha-reductase (type 1) messenger ribonucleic acid expression in rat brain: early presence in germinal zones. Endocrinology 137: 2718-2730.
54. Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, et al. (2006) Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 103: 14602-14607.
55. Pinna G, Agis-Balboa RC, Doueiri MS, Guidotti A, Costa E, (2004) Brain neurosteroids in gender-related aggression induced by social isolation. Crit Rev Neurobiol 16: 75-82.
56. Pomata PE, Colman-Lerner AA, Baranao JL, Fiszman ML, (2000) In vivo evidences of early neurosteroid synthesis in the developing rat central nervous system and placenta. Brain Res Dev Brain Res 120: 83-86.
57. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, et al. (2006) The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer's Disease. Biol Psychiatry 60: 1287-1294.
58. Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, et al. (2010) Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta 1801: 951-959.
59. di Michele F, Longone P, Romeo E, Lucchetti S, Brusa L, et al. (2003) Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol Sci 24: 172-173.
60. Luchetti S, Bossers K, Frajese GV, Swaab DF, (2010) Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 20: 945-951.
61. Barha CK, Ishrat T, Epp JR, Galea LA, Stein DG, (2011) Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury. Exp Neurol 231: 72-81.
62. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG, (2005) The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 22: 106-118.
63. Sayeed I, Guo Q, Hoffman SW, Stein DG, (2006) Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 47: 381-389.
64. Chen S, Wang JM, Irwin RW, Yao J, Liu L, et al. (2011) Allopregnanolone Promotes Regeneration and Reduces b-Amyloid Burden in a Preclinical Model of Alzheimer's Disease. Plos One 6: e24293.
65. Singh C, Liu L, Wang JM, Irwin RW, Yao J, et al. (2011) Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3×TgAD and nonTg mice. Neurobiology of Aging In press.
66. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933-2938.
67. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL, (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83: 165-175.
68. Viaro R, Marti M, Morari M, (2010) Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade. Exp Neurol 223: 473-484.
69. Carter RJ, Morton J, Dunnett SB, (2001) Motor coordination and balance in rodents. Curr Protoc Neurosci Chapter 8: Unit 8 12.